Eric Michael David | Chief Executive Officer of Gene Therapy
BridgeBio

Eric Michael David, Chief Executive Officer of Gene Therapy, BridgeBio

Appearances:



Day 1: 17th March 2026 @ 13:30

Chair's Remarks: Eric David, Chief Executive Officer of Gene Therapy, BridgeBio

Eric Michael David, Chief Executive Officer of Gene Therapy, BridgeBio

Day 1: 17th March 2026 @ 17:30

Panel Discussion: Broader Applications for Gene Therapies

Moderator: Uta Griesenbach, Professor of Molecular Medicine, Imperial College London
Joanne Ng, Professor of Genetic Therapy, UCL Institute of Neurology
Eric Michael David, Chief Executive Officer of Gene Therapy, BridgeBio
Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas
Salmaan Dalvi, Chief Executive Officer, Global Regenerative Medicine Society
Azadeh Kia, VP Gene Therapy Research, Beacon Therapeutics
Alison Clare, Senior Research Associate, University of Bristol
Samantha Barber, Chief Executive Officer, Gene People
last published: 12/Sep/25 15:35 GMT

back to speakers


Get Involved with Advanced Therapies Congress

 

To sponsor or exhibit

Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

To speak

Chris Shanks
Chris.Shanks@terrapinn.com
+44 207 092 1150